12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications.
Parkinson’s disease (PD) research is advancing rapidly, driven by innovations in neuroimaging, biomarker science, and therapeutic development. The field is moving beyond symptom management toward biologically grounded strategies for early diagnosis, disease staging, and modification. Biomarker-Driven Staging: The NSD-ISS Framework A major shift is underway in how PD is diagnosed and staged.
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias London, UK July.
Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme Alzheimer’s disease (AD) is the most common form of dementia, affecting millions globally. As research shifts increasingly toward earlier diagnosis and targeted interventions, including risk factors, biomarker-based frameworks have become essential tools for guiding both clinical research and drug development.
17 July 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025. The Company anticipates revenues to be at least £6.
10 June 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today outlined its role in the validation of a new Alzheimer’s Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics, Inc.
Beta-Amyloid and tau accumulation in Alzheimer’s disease Drug development for Alzheimer’s disease (AD) continues to face significant challenges, largely due to the limited availability of reliable biomarkers and the high risk of trial failure.
Why is harmonisation of imaging protocols important in Alzheimer's disease clinical trials? Harmonisation of imaging protocols is crucial in Alzheimer's disease clinical trials for several reasons. Firstly, it ensures consistency and accuracy across different trial sites, which is essential for reliable data collection and analysis.
1-8 of 167 results